457 related articles for article (PubMed ID: 26554404)
21. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
[TBL] [Abstract][Full Text] [Related]
22. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
25. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
[TBL] [Abstract][Full Text] [Related]
26. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
27. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
[TBL] [Abstract][Full Text] [Related]
28. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
[TBL] [Abstract][Full Text] [Related]
29. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
[TBL] [Abstract][Full Text] [Related]
30. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract][Full Text] [Related]
31. Dual
Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
[No Abstract] [Full Text] [Related]
32. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
Epstein LF; Chen H; Emkey R; Whittington DA
J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
[TBL] [Abstract][Full Text] [Related]
33. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
34. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
35. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
36. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Xia ZJ; Ji YC; Sun DQ; Peng X; Gao YL; Fang YF; Zhao XD; Wang WB; Ding J; Geng MY; Ai J
Acta Pharmacol Sin; 2021 Jun; 42(6):998-1004. PubMed ID: 32918045
[TBL] [Abstract][Full Text] [Related]
37. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
38. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
[TBL] [Abstract][Full Text] [Related]
39. Targeting ALK: The Ten Lives of a Tumor.
Versteeg R; George RE
Cancer Discov; 2016 Jan; 6(1):20-1. PubMed ID: 26747894
[TBL] [Abstract][Full Text] [Related]
40. Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Huang Q; Johnson TW; Bailey S; Brooun A; Bunker KD; Burke BJ; Collins MR; Cook AS; Cui JJ; Dack KN; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Johnson PS; Kania RS; Lam H; Lam JL; Le PT; Li Q; Lingardo L; Liu W; Lu MW; McTigue M; Palmer CL; Richardson PF; Sach NW; Shen H; Smeal T; Smith GL; Stewart AE; Timofeevski S; Tsaparikos K; Wang H; Zhu H; Zhu J; Zou HY; Edwards MP
J Med Chem; 2014 Feb; 57(4):1170-87. PubMed ID: 24432909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]